April 2021

Although aging a normal part of life, Alzheimer’s disease (AD) is not. Many individuals after the age of 65 or even before are diagnosed with AD. Alzheimer’s disease is a progressive disease that slowly destroys many abilities of the brain such as memory, thinking and even behaviours. While there are many treatments available for Alzheimer’s disease, there is no cure and the search for possible treatments, underlying mechanisms and pathology continue to be researched. Here, at Anogen, we would like to support your research on Alzheimer’s disease by offering a discount on possible treatment combos. Read our selection of exciting and new publications from 2020-2021 regarding Alzheimer’s disease.

Publications

Diagnostic Utility of Selected Serum Dementia Biomarkers: Amyloid β-40, Amyloid β-42, Tau Protein, and YKL-40: A Review

In this review paper, the authors examined several papers on the biomarker concentrations of amyloid β-40, amyloid β-42, tau protein and YKL-40. They examined several cross-sectional studies. The authors found that the results between the cognitive disorders group and control group for the amyloid β-40 and amyloid β-42 groups were incoherent. However, they found that in the patients with Alzheimer’s disease (AD), there was increased tau protein concentration. They also found that increased YKL-40 concentration was significant in those diagnosed with mild cognitive impairment which can progress to AD. The authors also found that the ratio of t-tau/Aβ-42 was also a significant biomarker in those with cognitive disorders such as Alzheimer’s disease.

Thus, monitoring the levels of tau protein, YKL-40 or the ratio of tau/Aβ-42 may prove to be beneficial in diagnosing cognitive disorders and treating them via drugs.

Target Research Combo: amyloid B-42, tau, YKL-40

Read full article here: Pubmed, October 2020

A peripheral neutrophil-related inflammatory factor predicts a decline in executive function in mild Alzheimer’s disease

There is a suggested role of neutrophils and inflammatory proteins in Alzheimer’s disease (AD). In this study, the authors investigate the role of these neutrophils and several inflammatory proteins in Alzheimer’s disease. The inflammatory proteins they tested include, Neutrophil gelatinase-associated lipocalin (NGAL), myeloperoxidase (MPO), interleukin-8 (IL-8), macrophage inflammatory protein-1 beta (MIP-1B) and tumor necrosis factor (TNF).

The authors found that all of these proteins combined created an inflammatory factor and it predicted the decline in executive function of patients with Alzheimer’s disease over the span of a year. In other words, these proteins are important biomarkers of AD and may be useful in predicting certain symptoms of the disease.

Target Research Combo: IL-8, TNF

Read full article here: Pubmed, March 2020

YKL-40 and neuron-specific enolase in neurodegeneration and neuroinflammation

Neurodegenerative diseases such as Alzheimer’s disease (AD) involve degeneration and inflammation of neurons. Although the processes and biomarkers underlying these processes are not fully understood. In this review paper, the authors highlight YKL-40 and neuron specific enolase (NSE) as playing a significant role in the monitoring and prognosis of many neurodegenerative diseases including Alzheimer’s disease.

The authors discovered that the increased levels of YKL-40 are related to the progression of the pathology. Reduced levels of NSE are correlated to low metabolic activity and increased death of neurons. Thus, both of these biomarkers give good insight into the prognosis and progression of AD.

Target Research Combo: YKL-40, NSE

Read full article here: Pubmed, July 2020

Relation between alpha‐synuclein and core CSF biomarkers in Alzheimer's disease

It is hypothesized that amyloid beta, tau protein and alpha synuclein are involved in Alzheimer’s disease and that these proteins all lead to the accumulation of one another. In this study, the authors did a follow-up of patients diagnosed with mild cognitive impairment and while some of them remained at this stage, others progressed to Alzheimer’s disease or another neurodegenerative disease. The authors measured for amyloid beta levels, tau protein and alpha synuclein (a-syn) with the human ELISA kits.

The authors found that the a-syn levels significantly correlated with tau protein in patients with AD. The tau proteins were significantly related to AD. Due to the exclusive correlation between a-syn and tau, the authors mention adding a-syn as a protein involved in the pathology of AD.

Target Research Combo: alpha synuclein, tau,

Read full article here: Alzheimer's association, December 2020

The emerging antibody markets

Monoclonal and polyclonal antibodies are antigen-specific targeting proteins. Due to their high specificity and selectivity, antibodies have always been used as outstanding tools for biomedical research and essential components of many diagnostics and therapeutics.

The global market for antibodies used in the research was estimated at about $2.3 billion in 2016 and is expected to reach $3.0 billion in 2022. Antibody-based drug discovery and development increased government and industry funding in new discoveries in “hot” research areas such as stem cell research, neuroscience, and cancer research, as well as other key drivers, will bring about an estimated annual growth rate of 4.8%.

Since the commercialization of the first therapeutic monoclonal antibody product in 1986, this class of biopharmaceutical products has been growing rapidly. More than 80 monoclonal antibody products have been approved in the US or other countries for the treatment of a variety of diseases. The combined worldwide sales have increased from $50 billion to $106 billion in 7 years since 2011.

Anogen has been in the antibody industry for 30 years

Anogen Yes Biotech Laboratories Ltd., a Canadian biotech company located in the Greater Toronto Area, has been producing antibody products for research, diagnostic and therapeutic applications for thirty years.

Anogen is a recognized leader worldwide in the biotech industry in the research & development of antibody-based products. Half of the top research antibody suppliers sell Anogen’s products. In the therapeutic antibody research field, Anogen has also been a reliable provider for many companies specialized in pharmaceutics and diagnostics.

Anogen has been ISO certified for 19 years to ensure that customers are provided with products and services of the highest quality.

Anogen has expanded the business to the Chinese market since 2006 and has invested in a number of promising antibody research projects by establishing new branches.

Anogen has a professional team and well-developed antibody research and manufacturing technology platform. All key members hold at least a Master’s degree and one-third of them have a Doctor’s degree. The founder of Anogen, Dr. Ye, is one of the leaders in cancer immunotherapy. The CSO Dr. Wang and Dr. Xu had been working as senior scientists at NIH USA for decades and have published hundreds of papers in the immunology research field.

Anogen has developed antibody products for various applications

Anogen has developed a cell bank of more than 1000 hybridomas, which can be cultured in vitro indefinitely, allowing relatively easy purification of large quantities of monoclonal antibodies. Based on this cell bank, Anogen has marketed more than 300 research antibodies and 60 ELISA kits. More than ten new products are launched every year.

As a research-focused company, Anogen also developed antibody-based diagnostics and therapeutics, including ABCREAM, an effective topical formulation of anti-IL-8 (CXCL8) monoclonal antibody for psoriatic skin, and neonatal TSH ELISA Kit, a diagnostic product used for quantitative measurement of TSH, licensed by Health Canada.

Anogen has a long-term collaborative history with major clinical research institutions and universities across North America and Europe. Anogen has also started new projects to develop laboratory-developed tests (LDT) and personalized cancer treatment, which Anogen believes are creative and important pathways for antibodies for clinical use.

Anogen’s research focuses on three main fields:

• Cytokine Storm Therapy: Antibodies can bind and remove excessive inflammatory cytokines released during trauma, transplant rejection, and acute infection.
• Alzheimer’s Disease (AD): Use an antibody to lower Aβ42 peptide levels in AD patients to improve cognitive deficits.
• Cancer Immunotherapy: Personalized treatment for various cancers.

There are nine projects in Anogen’s pipeline:

Anogen has developed dozens of mAbs with high specificity and selectivity that demonstrate great potential to be developed into novel antibody-based products as diagnostics and therapeutics

• mAbs against IL-8 and MCP-1for SARS/ARDS
• ABCREAM registration in the U.S and Europe market
• mAb against IL-17A for psoriasis treatment
• Skincare product using mAbs anti-IL-8 and TNF-α for allergic skin ailments
• Mabs against Aβ42 and Tau for AD prevention
• PD-1 and PD-L1 checkpoint inhibitors for personalized cancer treatment
• Research on cytokines in the tumor microenvironment for cancer diagnosis and treatment
• CD47 for personalized cancer treatment
• Immunoglobulin Y (IgY) in treating Helicobacter pylori infection

Anogen is a great opportunity to invest in the emerging antibody industry(Phase one of personalized diagnosis and treatment for cytokine storm)

Anogen is seeking to raise funds to accelerate its research projects and collaboration with partners to increase brand awareness and market share.